Can a quick radiation boost make CAR T-Cell therapy work better for lymphoma?

NCT ID NCT05621096

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether giving low-dose radiation before CAR T-cell therapy is feasible and safe for people with B-cell lymphoma that has come back or not responded to treatment. About 33 participants will receive two small doses of radiation, then standard CAR T-cell infusion. The main goal is to see if most patients can complete the full treatment plan, while also monitoring for serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
low-dose radiation and lisocabtagene maraleucel (CAR T-cell therapy)
What this could lead to
If successful, this approach could make CAR T-cell therapy more effective for patients with hard-to-treat B-cell lymphoma by using radiation to control the disease before infusion.
What could go wrong
This is a very early phase 1 trial with only 33 participants, so results may not apply to everyone. There are also risks of serious side effects like cytokine release syndrome and neurotoxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.